Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALVIN H SCHMAIER

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1578583134
CMS profile
116151
Location
CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$4,038.25

22 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,415.00 2
Food and Beverage $623.25 20

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALVIN H SCHMAIER

NPI 1578583134 · CMS profile ID 116151

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578583134?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALVIN H SCHMAIER, NPI 1578583134, CMS profile ID 116151. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578583134?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ALVIN H SCHMAIER, NPI 1578583134, CMS profile ID 116151. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578583134?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ALVIN H SCHMAIER, NPI 1578583134, CMS profile ID 116151, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1578583134?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

22 matching records · $4,038.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 22 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–22 of 22.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $23.9812/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939475969 CMS
Incyte Corporation $18.3911/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942999387 CMS
GENZYME CORPORATION $20.2811/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938856935 CMS
Lilly USA, LLC $24.8310/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917855181 CMS
Alexion Pharmaceuticals, Inc. $20.5110/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915552365 CMS
Celgene Corporation $21.1609/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932744745 CMS
PFIZER INC. $22.9309/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949364829 CMS
Rigel Pharmaceuticals, Inc. $24.2208/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962272889 CMS
Janssen Pharmaceuticals, Inc $16.0908/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886795871 CMS
Takeda Pharmaceuticals U.S.A., Inc. $121.7006/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955813741 CMS
Takeda Pharmaceuticals U.S.A., Inc. $121.7006/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965593955 CMS
EISAI INC. $20.4506/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908015639 CMS
E.R. Squibb & Sons, L.L.C. $16.0405/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932744713 CMS
HEMA Biologics, LLC $2,500.0005/20/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946078411 CMS
Pharmacyclics LLC, an AbbVie Company $27.9105/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890347171 CMS
HEMA Biologics, LLC $7.8405/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946078409 CMS
JAZZ PHARMACEUTICALS INC. $16.3505/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951357821 CMS
GlaxoSmithKline, LLC. $19.6905/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945067537 CMS
Takeda Pharmaceuticals U.S.A., Inc. $31.1304/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955813737 CMS
MorphoSys, US Inc. $23.6603/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962538815 CMS
Merck Sharp & Dohme LLC $915.0003/23/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944538791 CMS
Genentech USA, Inc. $24.3903/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950794199 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11,745.16 49
PY2020 $6,914.51 15
PY2021 $266.32 14
PY2022 $4,038.25 22
PY2023 $1,138.61 31
PY2024 $688.63 25
PY2025 $603.30 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $750.00 1
PY2022 Principal investigator $28,548.00 14
PY2021 Principal investigator $48,225.00 11
PY2020 Principal investigator $87,010.25 20
PY2019 Principal investigator $26,451.25 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

14 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 06/21/2022 Non-covered Recipient Entity
UNIVERSITY HOSPITALS OF CLEVELAND
PROSPECTIVE AND RETROSPECTIVE, NON-INTERVENTIONAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF OBIZUR IN REAL-LIFE PRACTICE No dispute reported 06/30/2026 937170453
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 06/21/2022 Non-covered Recipient Entity
UNIVERSITY HOSPITALS OF CLEVELAND
PROSPECTIVE AND RETROSPECTIVE, NON-INTERVENTIONAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF OBIZUR IN REAL-LIFE PRACTICE No dispute reported 06/30/2026 937170455
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 06/21/2022 Non-covered Recipient Entity
UNIVERSITY HOSPITALS OF CLEVELAND
PROSPECTIVE AND RETROSPECTIVE, NON-INTERVENTIONAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF OBIZUR IN REAL-LIFE PRACTICE No dispute reported 06/30/2026 937170457
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 06/21/2022 Non-covered Recipient Entity
UNIVERSITY HOSPITALS OF CLEVELAND
PROSPECTIVE AND RETROSPECTIVE, NON-INTERVENTIONAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF OBIZUR IN REAL-LIFE PRACTICE No dispute reported 06/30/2026 937170459
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,800.00 04/26/2022 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 937158647
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,800.00 04/26/2022 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 937158649
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,100.00 04/26/2022 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 937158651
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,848.00 04/26/2022 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 937158653
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,750.00 04/26/2022 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 937158655
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,400.00 04/26/2022 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 937158657
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 04/26/2022 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 937158659
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 04/26/2022 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 937158661
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $700.00 04/26/2022 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 937158663
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,750.00 04/14/2022 Covered Recipient Teaching Hospital
UH CLEVELAND MEDICAL CENTER
A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS,SAFETY AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT No dispute reported 06/30/2026 937158645